Meta-analysis of the immunogenicity of inactivated quadrivalent influenza virus vaccine in people over 60 years old
10.3969/j.issn.1006-2483.2024.06.005
- VernacularTitle:60岁以上人群接种四价流感病毒灭活疫苗免疫原性的Meta分析
- Author:
Peng DENG
1
;
Xiaoai QIAN
1
;
Qiong LI
1
;
Da FENG
2
;
Beifang YANG
1
Author Information
1. Hubei Provincial Center for Disease Control and Prevention , Wuhan , Hubei 430079 , China
2. School of Pharmacy , Tongji Medical College , Huazhong University of Science and Technology , Wuhan , Hubei 430030 , China
- Publication Type:Journal Article
- Keywords:
Inactivated quadrivalent influenza vaccine;
Immunogenicity;
Safety;
Meta-analysis
- From:
Journal of Public Health and Preventive Medicine
2024;35(6):21-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the immunogenicity of inactivated quadrivalent influenza vaccine (QIV) in people over 60 years old. Methods Databases including PubMed, EMBASE, Cochrane Library, China Biology Medicine disc, Wangfang Database and China National for Biotechnology Information were searched for random control studies comparing and analyzing the immunogenicity and safety between QIV and inactivated trivalent influenza vaccine (TIV) in people over 60 years old. Meta-analysis of the included literature data was performed using Stata11.0 software. Results A total of 9 articles were included in this study. There was no difference in seroconversion rates (SCR) and seroprotection rates (SPR) for the same vaccine strain after inoculation between QIV and TIV, while for the B vaccine strain (B/Victoria or B/Yamagata) not included in TIV, the SCR and SPR of QIV were significantly higher: SCR RR of 2.04 (95%CI:1.48~2.83) and SPR RR of 1.21 (95%CI:1.11~1.31) for B/Victoria; SCR RR of 2.35 (95%CI:2.04~2.69) and SPR RR of 1.12 (95%CI:1.02~1.23) for B/Yamagata. Conclusion For people over 60 years old, QIV has good immunogenicity, and produces better immunogenicity against influenza B vaccine strains not included in TIV.
